



Advanced therapies for Parkinson disease: Duodopa

Nov 18 2020

Tara Rastin, MD, FRCPC

Movement Disorders Specialist

University of British Columbia & Vancouver Coastal Health Authority

Djavad Mowafaghian Centre for Brain Health

Pacific Parkinson Research Institute

Faculty/Presenter Disclosure

I have nothing to disclose.

Webinar Outline

- What is Parkinson disease & what are its symptoms?
- How is Parkinson disease treated?
- When are advanced therapies for Parkinson disease indicated?
- What is levodopa continuous intestinal gel (LCIG)/Duodopa?
How does it work?
- Is LCIG right for me?
- Q & A

What is Parkinson disease?

- Parkinson disease is a **neurodegenerative** condition, with **loss of dopamine-producing cells** and accumulation of specific protein within brain cells (called **Lewy bodies**)
 - neuro-: brain disorder
 - degenerative: progressive (slowly, over years and decades)
 - loss of dopamine
 - accumulation of a protein called alpha-synuclein
- Parkinson disease is the second most common neurodegenerative disorder, after Alzheimer disease
- ~100,000 Canadians living with Parkinson disease (0.3% of population)
- ~10,000 newly diagnosed Canadians per yer

What are the symptoms of Parkinson disease?

- **Symptoms are very variable!**
 - There are many symptoms possible, but **one individual does not necessarily develop/experience all the symptoms**
 - Symptoms within one individual also change over time
- **Motor symptoms:**
 - Slowness of movement, stiffness, resting tremor, change in sense of balance
 - Slowness of movement **can manifest in various ways**: decreased arm swing or stride when walking, running or playing sports, smaller/cramped handwriting, decreased dexterity with manual hobbies or tasks (e.g., drawing, knitting, applying makeup, chopping/cooking, building models, mechanical work...), reduced facial expression, changes in speech, changes in swallowing, drooling
- **Non-motor symptoms:**
 - Common, and likely under-recognized (more on the next page)

What are the symptoms of Parkinson disease?

Possible Non-motor symptoms

- Constipation
- Sleep disorders (including REM-behaviour sleep disorder)
- Poor sense of smell
- Fatigue, low energy levels
- Mood disorders
- Pain
- Changes in bladder control
- Drop in blood pressure when standing, lightheadedness/fainting
- Cognitive changes
- Hallucinations
- Impulse control disorders

How is Parkinson disease treated?

- Cures or disease-modifying/halting therapies do not exist, yet
- However, many symptoms can be controlled with a combination of:
 - medications (**typically aiming to “replace” dopamine**)
 - regular exercise (very important, but not the focus of this webinar)
- Note:
Some non-motor symptoms respond to dopamine-related therapy but many do not and should be treated separately, for example:
 - Constipation
 - Mood disorders
 - Disruptive sleep disorders
 - Low blood pressure
 - Bladder symptoms (especially when in combination with enlarged prostate)
 - Hallucinations, other cognitive changes

Levodopa/carbidopa treats symptoms by 'replacing' dopamine

- **Levodopa/carbidopa** was a major breakthrough in symptomatic treatment of Parkinson disease in the 1960s
- Levodopa is converted to dopamine in the brain (carbidopa prevents conversion to dopamine outside the brain, to reduce side effects such as nausea and low blood pressure)
- Levodopa remains the most effective/potent medication available
- Everyone with Parkinson disease eventually requires levodopa, but very early in disease symptoms may be controlled with other agents alone

More about levodopa...

- Symptoms that improve with levodopa are called **levodopa-responsive**
 - These are often motor symptoms such as stiffness, slowness, tremor, but sometimes non-motor symptoms too such as soreness/pain, sweating, episodic anxiety, bladder urgency, etc.
- Initially, there is a **long-duration effect**
 - Overall improvement noted after days/weeks of treatment, no worsening noted if the odd dose is missed, but clear worsening if medication stopped or reduced after days/weeks
- With disease progression, patients become more aware of a **dose-dependent response**
 - symptoms improving and returning with each dose of medication every few hours
 - **“off” periods** are times when medication effects have “worn off” and symptoms return
 - motor fluctuations refer to frequent cycling between “on” and “off” periods, and/or presence of bothersome **dyskinesias** (more on the next slide)


More about levodopa and dyskinesia

- With increased duration of disease, patients can experience dyskinesia:
periods of excess rocking/writhing movements correlating in time with doses of levodopa
 - https://www.youtube.com/watch?v=XXLbGT_DfU
- Our current understanding is that dyskinesia correlate best with longer disease duration and higher individual doses of levodopa, rather than cumulated levodopa exposure
- With advanced disease, “off” periods and severe dyskinesia can alternate as levodopa blood levels rise and fall

Therapeutic window narrows as PD advances

The therapeutic window of levodopa becomes increasingly narrow⁴

More frequent doses of oral levodopa are required to reduce bradykinesia, but increased administration can increase dyskinesia



Reprinted by permission from Macmillan Publishers Ltd: *Nat Clin Pract Neurol*. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW, Obeso JA, Stocchi F. Vol. 2(7) copyright 2006.

Therapies for advanced Parkinson disease (summary slide)

- When severe dyskinesias and/or frequent “off” periods occur, the following advanced therapies may be helpful:
 - **Levodopa continuous gel intestinal (LCIG)/Duodopa**
 - Works for symptoms that respond well to levodopa (i.e., levodopa-responsive symptoms)
 - Used when frequent wearing-off and/or severe dyskinesia are interfering with quality of life
 - Cognitive impairment is less of a concern than in deep brain stimulation
 - **Presence of a care partner is important**
 - **Deep brain stimulation** (not the focus of this webinar)
 - Pacemaker connected to electrodes implanted in the brain, delivering a small electrical current to specific brain regions
 - Symptoms that respond well to DBS are symptoms that are levodopa-responsive! (i.e., DBS is not for everyone and does not fix all problems)
 - Poor overall health, more advanced age, cognitive impairment, psychiatric symptoms, and certain midline motor symptoms such as freezing of gait and soft speech can be reasons to avoid DBS

Levodopa/carbidopa intestinal gel (LCIG) - Duodopa

LCIG or Duodopa is used in the treatment of advanced Parkinson disease, where frequent “off” periods or motor fluctuations in spite of maximal/optimized oral therapies.

Good levodopa response is necessary:
Levodopa-unresponsive symptoms will not improve with LCIG



A. Pump; B. Cassette; C. PEG; D. J-tube

How does LCIG work?

- A tube (called a PEG-J tube) is placed through the stomach wall, with its tip lying in the small intestine
- Pump is attached to the tube
- Cassettes containing levodopa gel are connect to the pump, and levodopa is pumped at a set constant rate into the small intestine



Benefits continuous intestinal infusion may provide

- Stabilize levodopa concentrations in the bloodstream, to stay within the therapeutic window
 - More “ON” time/less “OFF” time
 - Reducing bothersome dyskinesia
- Bypasses the stomach to avoid the effects of slowed or delayed gastric emptying



Is LCIG right for me?

- Are there levodopa-responsive symptoms, but too much wearing off and/or bothersome dyskinesia in spite of optimizing oral medications?
 - LCIG does not improve symptoms that do not respond to levodopa
 - **Need to be able to reliably report “off” periods and dyskinetic periods**
 - symptom diaries (example on the next slide)
- Are there reasons that make it impossible or unsafe to place a PEG-J tube? (e.g., psychosis/severe agitation, previous abdominal surgery or intra-abdominal infections, etc.)
- Patient preference: PEG-J tube appearance & care, need for a pump, etc.
- Other practical considerations:
 - **Engaged care partner**
 - Local HCP willing & able to provide assessment, basic stoma care, physically make pump adjustments; ability to travel for assessments & titration
 - Local GI care

- +3 Extra movement may interfere with voluntary movement
- +2 Clear extra movement / moving continuously even in rest
- +1 Visible small extra movements / can be intermittent
- 0 On without symptoms (on without dyskinesia)

- 1 Patient feels rigidity / slow movement / no arm swinging
- 2 Remarkable slowness / may need assistance when arising or walking
- 3 Can't arise or walk / may move some extremities but with remarkable slowness

[illegible]

0

1-moderate

2-severe

[illegible]

C

1-moderate
2-severe

Dystonia
0
1-moderate
2-severe

	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	00	01	02	03
DOSE TAKEN			X			X			X			X			X			X						

The basic process to starting LCIG

- Evaluation by a movement disorders specialist at a centre offering LCIG titration
- If eligible:
 - Referral to Abbvie community resource nurse for pump related education
 - Referral to GI specialist for PEG-J tube placement
 - Slightly different approaches to initial titration exist; at our centre:
 - 2-4 weeks after PEG-J placement, outpatient titration over 3-4 days
 - Approximately 8-9am – 430pm at our centre with a nurse, 3-4 days in a row
 - Care partner in attendance, for education, support, and to help with travel to & from
 - Physician in close communication with nursing to find appropriate rate of infusion
 - Further education re: pump, stoma care, etc

Questions & Discussion

Thank you for your attention